当前位置: 首页 > 期刊 > 《上海医药》 > 2011年第7期
编号:12088643
碳青霉烯类抗生素的发展与展望(3)
http://www.100md.com 2011年7月1日 《上海医药》 2011年第7期
     [11]Mouton JW,Touzw DJ,Horrevorts AM,et al. Comparative pharmacokinetics of the carbapenems:Clinical implications[J].Clin Pharmacokinet,2000,39(3):185-201.

    [12]杜贯涛,刘广军. 多尼培南药理作用与临床应用[J].医药导报,2009,28(10):1324-1326.

    [13]Horiuchi M,Kimura M,Tokumura M,et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic,in comparison with beta-lactam antibiotics[J].Toxicol,2006,222(1-2):114-124.

    [14]Fuchs PC,Barry AL,Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical center[J].Antimicrob Agents Chemother,2001,45(6):1915-1918.

    [15]Panknch GA,Davies TA,Jacobs MR,et al. Antipeneumococoal activity of ertapenem (MK-0826) compared to those other agents[J].Antimicrob Agents chemother,2002,46(1):42-46.

    [16]张文君,吴文芳,冯小龙. 新型口服碳青霉烯类抗菌药物——泰吡培南酯[J].河北医药,2010,32(18):2596-2599.

    [17]Koga T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa[J].Antimicrob Agents Chemother,2008,52(8):2849-2854.

    (收稿日期:2011-05-03), 百拇医药(董耘婷 张永信)
上一页1 2 3